- SI-BONE (NASDAQ:SIBN) initiated with Buy rating and $25 (36% upside) price target at Canaccord Genuity.
- Amarin (NASDAQ:AMRN) price target (BUY) raised to $51 (142% upside) at H.C. Wainwright after release of REDUCE-IT results. Shares are down 15% premarket on robust volume as investors absorb the data. Apparently, there are questions about the placebo group.
- Adamis Pharmaceuticals (NASDAQ:ADMP) downgraded to Neutral with a $2.50 (11% downside risk) price target at B. Riley FBR citing the slow ramp of Symjepi and soft performance of its compounding business.
- Nobilis Health (NYSEMKT:HLTH) downgraded to Hold at Benchmark.
- Infinity Pharmaceuticals (NASDAQ:INFI) downgraded to Underweight at JPMorgan following underwhelming data on IPI-549 + BMY's Opdivo (nivolumab).
- Pacific Biosciences of California (NASDAQ:PACB) downgraded to Neutral with an $8 (3% upside) price target at Cantor Fitzgerald.
- Achaogen (NASDAQ:AKAO) downgraded to Neutral with a $3 (33% upside) price target at H.C. Wainwright after its Q3 miss.